Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Completed · Phase 1

Conditions studied: Malignant Disease

In brief

Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.

Key facts

Study ID

NCT00881166

Run by

Astex Pharmaceuticals, Inc.

People needed

101

Starts

2007-11-01

Expected to finish

2009-12-01

Last updated by the study team

2024-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib.
• Must be able to read, understand, and sign the IRB approved Informed Consent Form.
• At least 18 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.

You may not qualify if…

• Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ.
• History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction.
• Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists.
• Received prior radiation therapy within the past 4 weeks.
• Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.
• Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.

Where it is running

• Premiere Oncology — Scottsdale, Arizona, United States
• Premiere Oncology — Santa Monica, California, United States
• Audie Murphy Veterans Memorial Hospital (VA) — San Antonio, Texas, United States
• CTRC at the UT Health Science Center at San Antonio — San Antonio, Texas, United States
• South Texas Accelerated Research Therapy (START) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.